In a report released today, Graham Doyle from UBS maintained a Buy rating on ConvaTec (CTEC – Research Report), with a price target of p345.00.

The surge in the anti-biofilm wound dressing market is largely attributed to the rising prevalence of acute and chronic wounds. As these conditions become more common, the need for innovative and ...

Since its initial public offering, Convatec has followed a familiar playbook to press its advantage in advanced wound care and to enhance its ostomy business. By and large, we like Convatec’s ...

ConvaTec (CTEC) has stayed resolutely under the radar in recent years, despite building up a portfolio of products that has ultimately propelled it into the FTSE 100, following a successful IPO in ...

(Sharecast News) - Wound care specialist Convatec raised its guidance for the 2024 financial year on Tuesday, following robust sales growth across its divisions. The FTSE 100 company said that for ...

In 2023, ConvaTec reported revenue of USD2.14 billion ... deliver a mid-20s operating margin in 2026 or 2027." Advanced Wound Care delivered high-single digit organic growth, driven by high ...

ConvaTec’s divisions, including Advanced Wound Care and Continence Care, continue to show promising growth, supported by new product introductions and strategic market initiatives. For further ...